WHO’s 2023 NSS guideline. The whole verdict turns on two moves: the comparator decides the effect, and the discordance between short-term trials and long-term cohorts is left genuinely open — not resolved either way. NSS are defined as «all synthetic and naturally occurring or modified non-nutritive sweeteners that are not classified as sugars» (acesulfame K, aspartame, sucralose, saccharin, stevia, neotame, cyclamates, advantame); sugar alcohols/polyols are excluded. (World Health Organization, 2023)
The recommendation
«WHO suggests that non-sugar sweeteners not be used as a means of achieving weight control or reducing the risk of noncommunicable diseases (conditional recommendation).» (World Health Organization, 2023)
- Conditional recommendation, LOW certainty overall — both stated plainly: «The recommendation is based on evidence of low certainty overall». Read them together — this is a suggestion against on weak evidence, not a strong recommendation against. It says the expected value of using NSS for weight control is not positive on current evidence, not that NSS are demonstrated to harm. (World Health Organization, 2023)
- Scope guard — does NOT apply to people with existing diabetes (excluded from the reviewed evidence), and does not apply to NSS in medicines/hygiene products. Weight control means both weight loss in overweight/obesity and preventing unhealthy gain. (World Health Organization, 2023)
- Class-level, not per-sweetener. The recommendation covers NSS «as a class of compounds», because
«the evidence is currently insufficient to make recommendations for individual NSS» — even though each
has a distinct structure and «may have different physiological effects in humans». So a finding on
saccharin or aspartame is not automatically a finding on stevia.
type-B(one label, chemically distinct objects). (World Health Organization, 2023)
The comparator IS the effect (adults, RCTs)
The single most important reading of the trial evidence: NSS only lowers weight when it displaces sugar, and the effect shrinks toward null the closer the trial gets to the real-world question of replacing sugar with NSS.
effect_measure: body weight MD -0.71 kg (95% CI -1.13 to -0.28), 29 RCTs, n=2433; BMI -0.14 kg/m2 (-0.30 to 0.02), ns
population_and_comparator: adults; higher vs lower/no NSS in any manner (pooled across comparators)
outcome: body weight / BMI (surrogate for sustained-weight / NCD outcomes — see below)
uncertainty: Low certainty (RCTs); most trials <=3 months
certainty: Low
confidence: low(World Health Organization, 2023)
The pooled -0.71 kg dissolves once the comparator is pinned:
- vs free sugars → largest effect. «with the largest effects when NSS were compared with sugars. However, NSS compared with water showed no effect on body weight and a non-significant increase in BMI».
- vs water / nothing / placebo → no effect. «NSS compared with water showed no effect on body weight and a non-significant increase in BMI»; «When NSS were compared with nothing/placebo or water … no effects on body weight or BMI were observed.»
- As an actual sugar replacement → attenuates to null. In the RCTs that instructed habitual sugar consumers to switch to NSS versions, «the effect on body weight was significantly weakened … and an effect on BMI was no longer observed» — quantified as body weight MD -0.61 kg (95% CI -1.28 to 0.06), non-significant, BMI -0.01 (-0.38 to 0.35). (World Health Organization, 2023)
Mechanism is displacement, not the molecule. The weight effect «is mediated at least in part by lower energy intake as a result of decreased free sugars intake, rather than primarily by an inherent property of NSS» — a significant weight/BMI difference appeared «only … in trials that reported a reduction in energy intake, and energy intake was only significantly different in the arms of trials that compared NSS with free sugars». Energy intake fell -569 kJ/day (95% CI -859 to -278) and sugars intake -38.4 g/day (-57.8 to -19.1) — but only vs sugar, not vs water/placebo. (World Health Organization, 2023)
The RCT-vs-cohort discordance (adults)
The signature tension in the whole file: short-term trials show a small benefit; long-term observational cohorts show the opposite-signed associations with hard disease.
| Outcome | RCT (short-term) | Cohort (long-term; ~13 yr AVERAGE follow-up, range 2 to >30 yr) | Cohort certainty |
|---|---|---|---|
| Body weight | MD -0.71 kg (-1.13 to -0.28) | MD -0.12 / -0.01 kg, ns | Very low |
| BMI | -0.14 kg/m2, ns | +0.14 (0.03 to 0.25) | Very low |
| Incident obesity | — | HR 1.76 (1.25 to 2.49) — a 76% higher risk | Low |
| Type 2 diabetes (beverages) | glucose/insulin/HbA1c all null | HR 1.23 (1.14 to 1.32) | Low |
| Type 2 diabetes (tabletop) | — | HR 1.34 (1.21 to 1.48) | Low |
| CVDs | BP / LDL null in RCTs | HR 1.32 (1.17 to 1.50) | Low |
| Stroke | — | HR 1.19 (1.09 to 1.29) | Low |
| CVD mortality | — | HR 1.19 (1.07 to 1.32) | Low |
| All-cause mortality | — | HR 1.12 (1.05 to 1.19) | Very low |
| Cancer (any) | — | HR 1.02 (0.95 to 1.09) — null | Very low |
| Cancer mortality | — | HR 1.02 (0.92 to 1.13) — null | Very low |
| Bladder cancer (saccharin, case-control) | — | OR 1.31 (1.06 to 1.62) | Very low |
(World Health Organization, 2023)
Two things the table says on its own:
- The RCT biomarkers are flat. Fasting glucose MD -0.01 mmol/L (-0.05 to 0.04, Moderate), fasting insulin -0.49 pmol/L (-4.99 to 4.02), HbA1c 0.02%, LDL 0.03 mmol/L, systolic BP -1.33 mmHg (ns) — no short-term cardiometabolic signal in either direction. The insulin/glucose route is quiet, which is why a CGM sees nothing (-> Continuous Glucose Monitoring as a Health Intervention).
- Cancer is null in cohorts — the overall-cancer association is flat (HR ~1.02). The saccharin-bladder case-control signal is the exception, at very low certainty. The aspartame/cancer hazard question is not in this guideline (see gap below).
How WHO handles the discordance — the load-bearing appraisal point
This is where symmetric standards bite: WHO does not wave the cohorts away as reverse causation, and it does not accept them as proven harm either. It ran the check and returned a partial verdict.
-
Why short-term weight loss is not banked as benefit: «weight loss and maintenance of a healthy weight must be sustained over the long term to have a meaningful impact on health», so «evidence of minor weight loss or reduced BMI over several months or less … does not represent a health benefit». The trial benefit is on a surrogate (short-term weight), and WHO declines to let it stand for the sustained outcome (-> Surrogate Outcomes). «The discordant results between the RCTs and prospective cohort studies suggest that the small amount of weight loss … in short-term experimental settings may not be relevant to … long-term NSS use in the general population.» (World Health Organization, 2023)
-
The reverse-causation check was RUN — and the association survived it (weakened). Reverse causation here = «those already at elevated risk of disease initiated or increased use of NSS because of their risk status, rather than NSS leading to increased risk in otherwise healthy or low-risk individuals» (people already heavy/dysglycaemic switch to sweeteners because of their condition). Study authors attacked it: adjusting for BMI, stratifying by weight, excluding those who lost weight before baseline, and dropping early follow-up years. The result was mixed — «some results were attenuated, some were strengthened» — but «in the majority of studies, particularly for type 2 diabetes, associations persisted … in fully adjusted models». WHO’s conclusion:
«It was concluded that, although reverse causation and residual confounding may be contributing factors, the available evidence suggests that the associations observed between NSS use and health outcomes in observational studies cannot be dismissed as being solely a result of reverse causation or residual confounding.» (World Health Organization, 2023)
-
The conservative move. «Because of lack of certainty about the overall balance … including the possibility that reverse causation may have contributed to one or more of the associations …, a conservative approach was taken, leading to a conditional recommendation.» The uncertainty about which direction the cohort arrow points is exactly what makes the recommendation conditional rather than strong. (World Health Organization, 2023)
The honest read (symmetric standards). Do not report this as the cohorts are just reverse causation — WHO explicitly refused that framing. Nor as NSS cause diabetes and CVD — the certainty is Low/Very-low and the RCT biomarkers are flat. The defensible statement is: the long-term association is unexplained, cannot be fully attributed to reverse causation, and is not established as causal. This is the The U-Shaped Association Artifact machinery applied and returning not-dissolved, which is a different outcome from alcohol (dissolved) — file it there.
The microbiome route is now evidenced — and it is CAUSAL (Suez 2022) [2026-07-29]
Suez is the worked microbiome-causation template the fabric’s microbiome nucleus (Gut Microbiome and Health) holds up as the standard — a composition shift followed through to an outcome and confirmed by transplant. WHO named this gap (a sweetener-microbiome RCT was the awaited design — the wiki’s paraphrase, not WHO’s words). Suez 2022 (Cell) fills it with a randomized controlled trial — 120 NNS-avoiding healthy adults given saccharin, sucralose, aspartame or stevia for 2 weeks at «doses lower than the acceptable daily intake», vs vehicle-glucose or no-supplement controls — and it changes the reverse-causation picture materially:
- NNS are not inert. Each of the four «distinctly altered stool and oral microbiome and plasma metabolome, whereas saccharin and sucralose significantly impaired glycemic responses» vs controls. (Suez et al., 2022)
- Saccharin and sucralose «impaired glycemic responses»; aspartame and stevia shifted the microbiome
but did not significantly move glucose in the window — the class splits, vindicating WHO’s
type-Brefusal to treat NSS as one object. (Suez et al., 2022) - The effect is causal, not reverse causation. Germ-free mice colonized with stool from high- vs low-responding humans reproduced the donors’ glycemic responses — a microbiome-transfer causal step. And it is personalized: responders and non-responders within each arm. (Suez et al., 2022)
What this does and does NOT do to WHO’s open verdict (BLOCKING parameter table — different quantities):
| Parameter | WHO cohort signal | Suez 2022 | Same quantity? |
|---|---|---|---|
| Design | prospective cohort (observational) | RCT + gnotobiotic causal transfer | NO |
| Exposure contrast | habitual high vs low NSS users | randomized 2-week NNS vs control | NO |
| Endpoint | hard outcomes (T2D HR 1.23, CVD 1.32, mortality 1.12) | short-term glycemic response (OGTT/CGM) | NO — outcome vs surrogate |
| Causal status | reverse causation cannot be dismissed, not confirmed | causal (microbiome transplant) on the surrogate | NO |
| Population effect | population association | personalized (responders only) | NO |
Defensible synthesis (type F — refinement of WHO’s OPEN verdict): Suez shows a real causal pathway (NNS -> microbiome -> glycemia) exists in humans, so the long-term cohort signal is less dismissible as pure reverse causation — WHO’s refusal to wave the cohorts away now has a mechanism behind it. But Suez does not confirm the hard-outcome harm: its endpoint is a 2-week glycemic surrogate, the effect is personalized, and causal-on-the-marker is not causal-on-diabetes (Surrogate Outcomes). So the honest update is a causal glycemic mechanism is now demonstrated for saccharin/sucralose; the T2D/CVD/ mortality outcomes remain unproven — the OPEN verdict narrows, it does not close.
The aspartame / cancer signal WHO deferred (Debras cohort + narrative review) [2026-07-29]
WHO deferred the aspartame/cancer question to IARC/JECFA. Two lower-tier sources now populate it — without resolving it:
- Debras 2022 (NutriNet-Sante, 102,865 adults): total artificial sweeteners -> «overall cancer (HR for higher consumers versus non-consumers = 1.13 [95% CI 1.03 to 1.25], P-trend = 0.002)»; aspartame HR 1.15 (1.03-1.28), acesulfame-K 1.13 (1.01-1.26), breast cancer 1.22 (1.01-1.48). (Debras et al., 2022) But this is observational, small in absolute terms, and — importantly — DISCORDANT with WHO’s own cohort table, where overall cancer was NULL (HR ~1.02). So the cohort cancer evidence is internally inconsistent (a null pooled estimate vs a positive single newer cohort), and Debras is the same self-selected, self-reported NutriNet-Sante cohort as the organic-cancer study (Organic vs Conventional Food) — same healthy-user caveat.
- Narrative safety review (Nutrients 2023): EFSA’s position is that «aspartame and its breakdown products are safe for human consumption at current levels of exposure»; the cancer association «is still highly controversial and under investigation». It adds the contraindications that matter at layer 3: phenylketonuria (forbidden), seizures/neurological conditions (caution), pregnancy (restrict). [EXTRACTED (aspartame-safety-review-nutrients-2023) chunk 01] It is a narrative review — regulatory summary and contraindication list, not independent quantitative evidence.
IARC 2023 — the primary hazard classification (now held) [2026-08-04]
The hazard-vs-risk distinction this section turns on is owned at concept altitude by Hazard Identification Is Not Risk Magnitude; aspartame is one of its two worked instances.
The primary IARC hazard evaluation (Lancet Oncol summary of Monographs Vol 134) is now held directly — not merely the reported label. IARC does hazard identification (can aspartame cause cancer at any dose, is the hazard excludable?), never dose/risk.
- Aspartame classified «possibly carcinogenic to humans» (Group 2B) on «limited» evidence for cancer in humans, «limited» in experimental animals, and «limited» mechanistic evidence — the weakest positive tier, on limited evidence across all three streams. (Riboli et al., 2023)
- The human signal is liver cancer (hepatocellular carcinoma). Via ASB-as-proxy cohorts; in a 10-European-country study each weekly 330 mL ASB serving carried a «6% increase in risk of hepatocellular carcinoma» (95% CI 3-9%). The comprehensively-assessed NutriNet-Sante cohort (= Debras above) reported breast/obesity-related/overall associations but not consistent across studies and did not assess liver. (Riboli et al., 2023)
- Why it stayed “limited”, not sufficient. Despite positive findings in confounder-controlled studies, the Working Group concluded «chance, bias, or confounding could not be ruled out» with reasonable confidence. Animal evidence was positive but design-questioned (litter effects) — a minority favoured Group 2A on the animal data. Mechanistic: oxidative stress, inflammation, angiogenesis, raised rodent insulin, some limited genotoxicity. (Riboli et al., 2023)
Hazard != risk, and 2B != “causes cancer” (type-B disambiguation). Two distinctions the headlines
collapse, kept apart here:
- Hazard vs risk. IARC answers could aspartame cause cancer under some conditions? (hazard); it does not answer does it, at the doses people consume? (risk — JECFA’s question). A Group-2B hazard flag is consistent with a “safe at normal intake” risk verdict; the two bodies answer different questions. The same hazard/risk split already recurs in the fabric for the IARC red-meat labels (processed = Group 1, red meat = Group 2A) -> Red Meat.
- 2B is the weakest positive tier. 2B «possibly» (limited evidence) sits below 2A «probably» (methyleugenol, in the same evaluation, on sufficient animal + strong mechanistic evidence) and below Group 1 «carcinogenic». Reading 2B as “aspartame causes cancer” inflates a limited-evidence, can’t-exclude-confounding hazard signal into a demonstrated dietary risk. Symmetric standards cut both ways: it is a finding (a positive hazard classification, not dismissible), but a weak one. (inferred from Riboli et al., 2023)
JECFA 2023 — the risk assessment (now held) [2026-08-04]
The regulatory risk counterpart, released the same day as IARC under the same WHO umbrella, is now held directly. JECFA answers is realistic dietary intake unsafe? (dose/risk), not IARC’s can it cause cancer at any dose? (hazard).
- ADI 0-40 mg/kg bw/day, reaffirmed. «The Committee concluded that the data evaluated at the present meeting indicated no reason to change the previously established ADI of 0-40 mg/kg bw for aspartame». It rests on a «no-observed-adverse-effect limit (NOAEL) of 4000 mg/kg bw per day, the highest dose tested, in a 104-week study in rats», with a 100-fold uncertainty factor (4000 / 100 = 40). (Joint FAO WHO Expert Committee on Food Additives, 2023)
- The mechanistic reason JECFA is unconcerned — no systemic exposure. «Aspartame is fully hydrolysed in the gastrointestinal tract … into three metabolites: phenylalanine, aspartic acid and methanol. The Committee therefore reaffirmed that there is no systemic exposure to aspartame after dietary exposure»; those metabolites «enter the systemic circulation at levels lower than those derived from consumption of common foods». The parent compound never reaches the bloodstream; the breakdown products are the same as, and lower than, those from ordinary food. (Joint FAO WHO Expert Committee on Food Additives, 2023)
- First-ever dietary-exposure assessment — the decision magnitude. «Dietary exposure estimates … at the mean of up to 10 mg/kg bw per day for children and 5 mg/kg bw per day for adults, and for high dietary exposures up to 20 mg/kg bw per day for children and 12 mg/kg bw per day for adults» «do not exceed the ADI», so «dietary exposure to aspartame does not pose a health concern». (Joint FAO WHO Expert Committee on Food Additives, 2023) So even a high-consuming adult (12 mg/kg/day) reaches only ~30% of the ADI, and ~333x below the animal NOAEL; the mean adult ~12%. (inferred from Joint FAO WHO Expert Committee on Food Additives, 2023) For a 70 kg adult the ADI equals ~2,800 mg/day; at ~180-200 mg aspartame per can of diet soda that is on the order of a dozen-plus cans per day sustained — .
Same evidence, opposite headline — a distinction, NOT a joined tension (parameter table). The public reading («IARC says cancer, JECFA says safe») looks like a contradiction; the table shows the two bodies agree on every shared quantity and differ only in the question each asks.
| Parameter | IARC (hazard) | JECFA (risk) | Same quantity? |
|---|---|---|---|
| Question answered | can aspartame cause cancer at any dose? (hazard) | is realistic dietary intake unsafe? (ADI / dose-risk) | NO — different question by design |
| Human cohort cancer evidence | «limited» evidence, liver/HCC; «chance, bias, or confounding could not be ruled out» | «not convincing»; «Reverse causality, chance, bias and confounding … cannot be ruled out»; «a consistent association … was not observed» | YES — same cohorts, same caveat |
| Soffritti/Ramazzini animal studies | positive but «limited» (design questioned, litter effects) | «of uncertain relevance and therefore cannot be used for the risk assessment» (natural-death protocol confounds with ageing) | YES — same studies, both discount |
| Output / verdict form | Group 2B classification (a hazard tier) | ADI 0-40 mg/kg reaffirmed; exposure <=12 mg/kg/day | NO — different output type |
Where the two bodies assess the same quantity (human cohort evidence + its caveat; the Soffritti
studies) they agree — same data, same limitations. Their bottom lines diverge only because they
answer different questions with different output types. Per the not-joined checks — (i) no shared
quantity is in opposition, (ii) different scope, consistent once matched — this is a distinction,
not a tension. The hidden insight: the apparent contradiction dissolves entirely under the
hazard-vs-risk frame — a Group-2B hazard flag on limited, confounding-not-excludable evidence is fully
consistent with a risk verdict that realistic intake is far below the safe bound. This reinforces (does
not clash with) the type-B hazard-vs-risk disambiguation above.
(Joint FAO WHO Expert Committee on Food Additives, 2023; inferred from Riboli et al., 2023)
CASHED [2026-08-04].
Decision relevance — substitution frame
- vs sugar: a small, short-lived weight benefit that fades to null in true-replacement trials. Better than sugar on weight, marginally, in the short run.
- vs water / unsweetened: no benefit. WHO’s preferred alternative is explicit: «Replacing free sugars in the diet with sources of naturally occurring sweetness, such as fruits, as well as minimally processed unsweetened foods and beverages … should be the preferred alternatives». Swapping sugar for NSS leaves «the overall quality of the diet … largely unaffected». (World Health Organization, 2023)
- NSS are «not essential dietary factors and have no nutritional value» — so the null-benefit finding carries no offsetting cost of not using them. (World Health Organization, 2023)
- Layer-3 caveat: for a person whose realistic alternative is sugar-sweetened soda and who will not switch to water, NSS is still the better of those two — the guideline optimizes a population question (don’t build policy on NSS), not this individual’s next drink.
Other strata
- Children: more limited; one good RCT showed body-fatness reductions, but pooled BMI z-score showed no effect (Moderate certainty); overall certainty across adult+child data judged Low. Two stevia RCTs showed lower dental-caries indicators.
- Pregnancy: higher NSS use associated with preterm birth, OR 1.25 (1.07 to 1.46), Low certainty (three cohorts, dose-response in two); offspring birth-weight/adiposity associations inconsistent. Extrapolated from adult evidence «without downgrading for indirectness». (World Health Organization, 2023)
Named gaps
- Aspartame / cancer HAZARD (IARC 2023) + RISK (JECFA 2023) — BOTH CASHED
[2026-08-04]. The IARC hazard evaluation (Group 2B, limited evidence, liver-cancer signal, confounding-not-excludable) and the JECFA risk assessment (ADI 0-40 mg/kg reaffirmed; realistic exposure ~1/3 of the ADI) are now both held directly — see the IARC and JECFA sections above. WHO NSS 2023 had deferred hazard/ADI to IARC/JECFA. The hazard-vs-risk relation resolved as a distinction, not a tension (parameter table above): the two bodies agree on every shared quantity and differ only in the question each answers. - Gut-microbiome / glycaemic route — CASHED
[2026-07-29]by Suez 2022 (RCT + gnotobiotic causal transfer): a causal NNS -> microbiome -> glycemia pathway is now demonstrated for saccharin/sucralose, on a short-term surrogate, personalized (see the microbiome section above). Appetite / cravings routes remain insufficient evidence.
Limits
- Now six sources. IARC 2023 (gold) is a hazard identification on limited evidence and JECFA 2023
(gold) a risk assessment — together they close the aspartame/cancer question WHO deferred, but
neither is a new hard-outcome estimate: IARC does not raise hard-outcome certainty, and JECFA’s
reassurance rests on a no-adverse-effect read of the same weak evidence plus the no-systemic-exposure
mechanism, not a demonstrated benefit. The other additions are surrogate/observational: Suez is an RCT
on a short-term glycemic surrogate (personalized); Debras is observational and discordant with
WHO’s null; the aspartame review is narrative. So the hard-outcome certainty on whether NSS help
is unchanged —
confidence: lowholds. What the aspartame pair adds is the cancer hazard + risk cleanly held and the hazard-vs-risk disambiguation completed as a distinction. - Open loop (R1): this grades the sources’ reasoning for coherence and source-fidelity; whether NSS actually move a hard outcome is a validity fact no operation here can see.
- Independence: Suez (Weizmann RCT group) and Debras (NutriNet-Sante) are genuinely independent of WHO and of each other — but they answer different questions (surrogate mechanism vs cohort cancer), so this is type-F refinement, not type-E convergence on one claim. WHO NSS stays NON-independent of the WHO free-sugars family (Free Sugars Intake). IARC and JECFA are NOT independent of each other — same WHO umbrella, same evidence base, released the same day — so their agreement where they overlap is shared-source, not type-E backing.
Self-critique [run 2026-07-29, second pass — the Suez/Debras/review additions]
- Over-claim check. Suez is explicitly NOT read as confirming the hard-outcome harm — the parameter table’s all-NO column gates it to causal on a surrogate, personalized; the OPEN verdict is said to narrow, not close. Debras is flagged as discordant with WHO’s own null cohort, not as proof of cancer risk. No superlative scoped to the vault.
- Laundered-E avoided. The additions are typed F (refinement), not E — Suez and Debras answer different questions and neither is independent backing for one claim; stated in Limits.
- Reverse-causation handling. The one genuinely new causal fact (microbiome transfer) is used only for the surrogate it measured; the leap to T2D/CVD is explicitly withheld.
- Symmetric standards. Debras (a signal in the “sweeteners are bad” direction) is held to the same observational/healthy-user discount as the organic-cohort was — not waved through because it fits the cautionary prior.
Self-critique [run 2026-08-04, third pass — the IARC 2023 hazard addition]
- No inflation of 2B. The IARC section states Group 2B is the weakest positive tier on limited evidence and that «chance, bias, or confounding could not be ruled out» — explicitly not read as “aspartame causes cancer”. Symmetric standards named in both directions (a finding, but a weak one).
- Hazard-vs-risk relation resolved as a DISTINCTION on the JECFA ingest
[2026-08-04]— not a prematuretensionat the IARC pass, and (correctly) not a tension at all: the JECFA parameter table shows the bodies agree on every shared quantity, so the not-joined checks fire. Recorded as a distinction, not a joined clash. - Type-B, not fabricated independence. The 2B<2A<1 ordering and hazard/risk split are marked (read off the classifications/grades in the one source), not laundered as cross-source convergence. IARC and Debras are not independent backing for one claim — IARC’s human evidence explicitly rests partly on the NutriNet-Sante (= Debras) cohort, so no type-E claimed.
- Provenance quality. The source PDF carries embedded line-numbers; long verbatim quotes avoided,
numerics stated as faithful
[EXTRACTED]paraphrase, short clean spans («possibly carcinogenic to humans»,«hepatocellular carcinoma»,«6% increase in risk of hepatocellular carcinoma») verified to locate viacite.py.
Self-critique [run 2026-08-04, fourth pass — the JECFA 2023 risk addition]
- Distinction, not a manufactured tension. The parameter table was built before the prose: the two
bodies agree on every shared quantity (human cohort evidence + caveat; the Soffritti animal studies)
and differ only in question + output type. The not-joined checks (i) + (ii) fire, so no
tensionwas filed — the predicted, correct outcome for a deliberately-complementary pair. No fake friction to fill a quota. - Independence not laundered. IARC and JECFA are explicitly flagged NON-independent (same WHO
umbrella, same evidence base, same day) — their agreement is shared-source, not type-E. No
[E-independent]token claimed. - No over-claim on safety. JECFA’s verdict is stated as no convincing evidence of adverse effect at
realistic intake (a risk-side null on the same weak evidence + the no-systemic-exposure mechanism),
NOT as proof aspartame is beneficial or as raising the hard-outcome certainty on whether NSS help.
confidence: lowunchanged. No superlative scoped to the vault. - Decision magnitude honestly bounded. The %-of-ADI and NOAEL-fold ratios and the 2,800 mg/day figure are marked arithmetic on JECFA’s quoted exposure/ADI/NOAEL numbers; the diet-soda-can illustration is explicitly flagged as NOT in the JECFA summary (added for grip, not attributed).
- Symmetric standards. The reassuring JECFA verdict gets the same scrutiny as the cautionary Debras/IARC signals — its ADI is shown to rest on a single old rat NOAEL + a 100-fold factor, and its cancer null on the same confounding-not-excludable cohorts IARC read the other way.
Appraising this observational evidence — the instrument [2026-07-31]
The sweetener cancer and glucose signals held on this page (the NutriNet-Sante cohort and the Suez RCT) are observational in the cancer arm; ROBINS-I (Risk of Bias Assessment Tools) is the appraisal instrument, with domain 1 (confounding / reverse causation — people switch to NSS because of weight or dysglycaemia) and domain 6 (measurement) the likely caps. Re-appraisal candidate on the RoB-tools page; not re-graded here.